AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Xilio Therapeutics Plunges 27.2% on Public Offering News
Generated by AI AgentAinvest Pre-Market Radar
Monday, Jun 2, 2025 6:37 am ET1min read
On June 2, 2025,
experienced a significant drop of 27.2% in pre-market trading, marking a notable decline in its stock performance.Xilio Therapeutics recently announced a proposed public offering, aiming to raise funds to advance the development of its product candidates and for working capital. This move is part of the company's strategy to secure additional financial resources to support its ongoing research and development efforts.
In addition to the public offering,
Therapeutics has signed a sales agreement with Leerink Partners, allowing the company to offer up to $50 million of its common stock in "at the market" offerings. This agreement provides Xilio with flexibility in raising capital and managing its financial needs.Xilio Therapeutics also unveiled updated Phase 2 data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in combination with Atezolizumab in patients with metastatic cancer. The updated data from the Phase 2 clinical trial of vilastobart was announced on May 31, 2025, highlighting the company's progress in its clinical development programs.
Ainvest Pre-Market Radar
Get the scoop on pre-market movers and shakers in the US stock market.
Latest Articles
SEALSQ Surged 8.29% Driven by 2026–2030 Roadmap for Silicon-Based Quantum Computing Systems
Dec.19 2025
Serve Robotics (SERV) Surges 5.97% on Bullish Oppenheimer Note
Dec.19 2025
AXT Inc. shares surge 13.35% on renewed earnings upside speculation amid supply chain adjustments
Dec.19 2025
PROK surged 5.11% on Dec. 19 2025 after HC Wainwright upgraded to Buy rating
Dec.19 2025
Tesla shares surge 3.45% as SpaceX orders 1,000-2,000 Cybertrucks for Starbase facility.
Dec.19 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet